Carol Briggs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carol Briggs has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
S. J. Machin
Haemostasis Research Unit University College London London UK
4 shared publicationsSamuel J Machin
Department of Haematology, University College London Hospital, London, UK
2 shared publicationsStefan Kunka
Department of Haematology, University College London Hospital, London, UK
2 shared publicationsB. Davis
Trillium Diagnostics LLC Brewer ME USA
1 shared publicationBruce H Davis
1 shared publicationC Pennaneach
1 shared publication
Latest Publications
- 25 March 2014
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 36 (6) , 613-627
ICSH guidelines for the evaluation of blood cell analysers including those used for differential leucocyte and reticulocyte counting
Summary: This revision is intended to update the 1994 ICSH guidelines. It is based on those guidelines but is updated to include new methods, such as digital image analysis for blood cells, a flow cytometric method intended to replace the reference manual 400 cell differential, and numerous new cell indices not identified morphologically are introduced. Haematology analysers are becoming increasingly complex and with technological advancements in instrumentation with more and more quantitative parameters are being reported in the complete blood count. It is imperative therefore that before an instrument is used for testing patient samples, it must undergo an evaluation by an organization or laboratory independent of the manufacturer. The evaluation should demonstrate the performance, advantages and limitations of instruments and methods. These evaluations may be performed by an accredited haematology laboratory where the results are published in a peer‐reviewed journal and compared with the validations performed by the manufacturer. A less extensive validation/transference of the equipment or method should be performed by the local laboratory on instruments prior to reporting of results.
- 25 March 2014
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 36 (6) , 613-627
ICSH guidelines for the evaluation of blood cell analysers including those used for differential leucocyte and reticulocyte counting
Summary: This revision is intended to update the 1994 ICSH guidelines. It is based on those guidelines but is updated to include new methods, such as digital image analysis for blood cells, a flow cytometric method intended to replace the reference manual 400 cell differential, and numerous new cell indices not identified morphologically are introduced. Haematology analysers are becoming increasingly complex and with technological advancements in instrumentation with more and more quantitative parameters are being reported in the complete blood count. It is imperative therefore that before an instrument is used for testing patient samples, it must undergo an evaluation by an organization or laboratory independent of the manufacturer. The evaluation should demonstrate the performance, advantages and limitations of instruments and methods. These evaluations may be performed by an accredited haematology laboratory where the results are published in a peer‐reviewed journal and compared with the validations performed by the manufacturer. A less extensive validation/transference of the equipment or method should be performed by the local laboratory on instruments prior to reporting of results.
- 31 July 2012
- Published by BMJ in Journal of Clinical Pathology
- Vol. 65 (11) , 1024-1030
Performance evaluation of the Sysmex haematology XN modular system
Background: The Sysmex XN haematology instrument performs automatic reflex testing, depending on sample results. A nucleated red blood cell (NRBC) count is provided on all samples. The instrument has a smaller footprint (34%) than previous Sysmex XE analysers. Methods: An evaluation comparing all results to the Sysmex XE-2100 and manual microscopic differential and morphology (n=390) was performed followed by a workflow study of 1000 samples to compare speed of operation and number of blood films reviews required from both systems. Results: The new features on the instrument are: (1) white cell and NRBC channel, all samples include the NRBC count; (2) white cell precursor channel: false positive flags for blasts, abnormal lymphocytes and atypical lymphocytes are reduced significantly without a statistical increase of false negatives; (3) low white cell count mode: suggested setting of 9 /l. An extended count is more precise and provides an accurate differential. Fluorescent platelet count is performed in a dedicated channel. If the red cell or platelet size histograms are abnormal or if the platelet count is low, then a fluorescent platelet count is automatically performed. Good correlation with the XE-2100 and manual differential was found and the improved results compared to the reference flow cytometric analysis for platelet counts, especially below 30×10 9 /l (XE-2100, R 2 =0.500; XN, R 2 =0.875). Conclusion: The XN showed reduced sample turnaround time of 10% and reduced number of blood films for examination, 49% less than the XE-2100 without loss of sensitivity with more precise and accurate results on low cell counts.
- 31 July 2012
- Published by BMJ in Journal of Clinical Pathology
- Vol. 65 (11) , 1024-1030
Performance evaluation of the Sysmex haematology XN modular system
Background: The Sysmex XN haematology instrument performs automatic reflex testing, depending on sample results. A nucleated red blood cell (NRBC) count is provided on all samples. The instrument has a smaller footprint (34%) than previous Sysmex XE analysers. Methods: An evaluation comparing all results to the Sysmex XE-2100 and manual microscopic differential and morphology (n=390) was performed followed by a workflow study of 1000 samples to compare speed of operation and number of blood films reviews required from both systems. Results: The new features on the instrument are: (1) white cell and NRBC channel, all samples include the NRBC count; (2) white cell precursor channel: false positive flags for blasts, abnormal lymphocytes and atypical lymphocytes are reduced significantly without a statistical increase of false negatives; (3) low white cell count mode: suggested setting of 9 /l. An extended count is more precise and provides an accurate differential. Fluorescent platelet count is performed in a dedicated channel. If the red cell or platelet size histograms are abnormal or if the platelet count is low, then a fluorescent platelet count is automatically performed. Good correlation with the XE-2100 and manual differential was found and the improved results compared to the reference flow cytometric analysis for platelet counts, especially below 30×10 9 /l (XE-2100, R 2 =0.500; XN, R 2 =0.875). Conclusion: The XN showed reduced sample turnaround time of 10% and reduced number of blood films for examination, 49% less than the XE-2100 without loss of sensitivity with more precise and accurate results on low cell counts.
- 5 July 2012
- Published by Wiley in British Journal of Haematology
- Vol. 158 (6) , 679-690
Where are we at with point‐ of‐ care testing in haematology?
Summary: Point‐of‐care testing (POCT) in haematology has continued to grow in popularity and uptake throughout the world. The increasing demand to reduce the turnaround time of test results, coupled with rapid improvements in technology, have led to the development of several devices that are designed for use in different clinical settings, with the hope of improving patient care. The most used POCT in haematology is measurement of haemoglobin concentration. Other POCT devices (used primarily in developing countries) for malaria screening and CD4+ T‐lymphocytes for quantification of human‐immunodeficiency‐virus are becoming the cornerstone for the diagnosis and management of these disorders. New devices are also available for red cell indices, white blood cell count and platelets. In this review clinical studies that validate the use of such devices will be discussed, as well as the advantages and disadvantages of POCT in haematology. A disadvantage of POCT is a lack of training, poor standardization in obtaining blood samples and insufficient internal/external quality assessment. As there is every reason to expect that POCT use will increase in all pathology disciplines, including haematology, it is imperative that systems are put in place to oversee these issues.
- 5 July 2012
- Published by Wiley in British Journal of Haematology
- Vol. 158 (6) , 679-690
Where are we at with point‐ of‐ care testing in haematology?
Summary: Point‐of‐care testing (POCT) in haematology has continued to grow in popularity and uptake throughout the world. The increasing demand to reduce the turnaround time of test results, coupled with rapid improvements in technology, have led to the development of several devices that are designed for use in different clinical settings, with the hope of improving patient care. The most used POCT in haematology is measurement of haemoglobin concentration. Other POCT devices (used primarily in developing countries) for malaria screening and CD4+ T‐lymphocytes for quantification of human‐immunodeficiency‐virus are becoming the cornerstone for the diagnosis and management of these disorders. New devices are also available for red cell indices, white blood cell count and platelets. In this review clinical studies that validate the use of such devices will be discussed, as well as the advantages and disadvantages of POCT in haematology. A disadvantage of POCT is a lack of training, poor standardization in obtaining blood samples and insufficient internal/external quality assessment. As there is every reason to expect that POCT use will increase in all pathology disciplines, including haematology, it is imperative that systems are put in place to oversee these issues.
- Open Access
- 21 April 2009
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 31 (3) , 277-297
Quality counts: new parameters in blood cell counting
Summary: Recently several parameters have been introduced to the complete blood count such as nucleated red blood cells, immature granulocytes; immature reticulocyte fraction, immature platelet fraction and red cell fragments as well as new parameters for detection of functional iron deficiency. Leucocyte positional parameters, which may diagnose specific diseases (e.g. differentiate between abnormal lymphocytes in leukaemia and viral conditions and may also detect malarial infection) are now available. At this time they are only used for research; however, generally such parameters later become reportable. One manufacturer’s routine analyser allows measurement of cells by flow cytometry using monoclonal antibodies. Currently, there are no accredited external quality assessment schemes (EQAS) for these parameters. For a number of parameters, on some instruments, there is no internal quality control, which brings into question whether these parameters should be used for clinical decision making. Other more established parameters, such as mean platelet volume, red cell distribution width and the erythrocyte sedimentation rate do not have EQAS available. The UK National EQAS for General Haematology held a workshop earlier this year in 2008 to discuss these parameters. Participants were asked to provide a consensus opinion on which parameters are the most important for inclusion in future haematology EQAS.
- 21 April 2009
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 31 (3) , 277-297
Open AccessQuality counts: new parameters in blood cell counting
Summary: Recently several parameters have been introduced to the complete blood count such as nucleated red blood cells, immature granulocytes; immature reticulocyte fraction, immature platelet fraction and red cell fragments as well as new parameters for detection of functional iron deficiency. Leucocyte positional parameters, which may diagnose specific diseases (e.g. differentiate between abnormal lymphocytes in leukaemia and viral conditions and may also detect malarial infection) are now available. At this time they are only used for research; however, generally such parameters later become reportable. One manufacturer’s routine analyser allows measurement of cells by flow cytometry using monoclonal antibodies. Currently, there are no accredited external quality assessment schemes (EQAS) for these parameters. For a number of parameters, on some instruments, there is no internal quality control, which brings into question whether these parameters should be used for clinical decision making. Other more established parameters, such as mean platelet volume, red cell distribution width and the erythrocyte sedimentation rate do not have EQAS available. The UK National EQAS for General Haematology held a workshop earlier this year in 2008 to discuss these parameters. Participants were asked to provide a consensus opinion on which parameters are the most important for inclusion in future haematology EQAS.
- Open Access
- 23 February 2009
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 31 (2) , 169-179
Measurement of CD4+T cells in point-of-care settings with the Sysmex pocH-100i haematological analyser
The decision to provide antiretroviral therapy to HIV‐positive patients mainly depends on the CD4+ T‐cell count, with therapy indicated at a cut‐off value of + T cells/μl blood. Monitoring patients is still a major problem in countries with limited resources where blood samples often have to be transported over long distances to regional referral centres in which the count can be performed on flow cytometers. We have evaluated a newly developed simple and inexpensive method for CD4+ T‐cell quantification. It is a variation of the Invitrogen T4 Quant kit, with manual isolation of nuclei from CD4+ T cells and subsequent counting on the small haematology analyser pocH‐100i, Sysmex. We have demonstrated that this new method is highly reproducible and gives stable and linear results over a wide range of CD4+ T‐cell concentrations. Method comparison to two different flow cytometers showed excellent correlation with concordances of about 93%. Overall, this method is rapid, easy to perform and offers a good reliable alternative to measurement by flow cytometry. The pocH‐100i has the additional benefit of providing a complete blood count with a three‐part white blood cell differential and software for patient data storage and handling.
- 23 February 2009
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 31 (2) , 169-179
Open AccessMeasurement of CD4+T cells in point-of-care settings with the Sysmex pocH-100i haematological analyser
The decision to provide antiretroviral therapy to HIV‐positive patients mainly depends on the CD4+ T‐cell count, with therapy indicated at a cut‐off value of + T cells/μl blood. Monitoring patients is still a major problem in countries with limited resources where blood samples often have to be transported over long distances to regional referral centres in which the count can be performed on flow cytometers. We have evaluated a newly developed simple and inexpensive method for CD4+ T‐cell quantification. It is a variation of the Invitrogen T4 Quant kit, with manual isolation of nuclei from CD4+ T cells and subsequent counting on the small haematology analyser pocH‐100i, Sysmex. We have demonstrated that this new method is highly reproducible and gives stable and linear results over a wide range of CD4+ T‐cell concentrations. Method comparison to two different flow cytometers showed excellent correlation with concordances of about 93%. Overall, this method is rapid, easy to perform and offers a good reliable alternative to measurement by flow cytometry. The pocH‐100i has the additional benefit of providing a complete blood count with a three‐part white blood cell differential and software for patient data storage and handling.
- 21 August 2008
- Published by Wiley in British Journal of Haematology
- Vol. 142 (6) , 904-915
Guidelines for point‐of‐care testing: haematology
Summary: This guideline provides a framework for the arrangement of point‐of‐care testing (POCT) services, previously known as near patient testing (patient self‐testing not covered). POCT is defined as any analytical test performed outside the laboratory. Primary users are often non‐laboratory healthcare workers. The guidance applies to units within hospitals as well as general practioner surgeries, community clinics and pharmacies. The head of the haematology laboratory or a point of care coordinator must take responsibility for all aspects of the POCT service, including quality and training. Depending on the size and nature of the POCT practice, a local POCT manager may also be required. Equipment selected should have received a successful independent performance evaluation. If an independent evaluation has not been performed the purchaser should assess the device according to the protocol in this document. POCT devices should generate results that are comparable to those of the local laboratory. An accredited external quality assessment programme and internal quality control system must be established. Manufacturers promoting POCT devices designed for non‐laboratory sites, e.g. pharmacies, should undertake training and annual competency assessment, perhaps using a web‐based system. A diagram to illustrate the stages for the implementation of a POCT service is illustrated.
- 21 August 2008
- Published by Wiley in British Journal of Haematology
- Vol. 142 (6) , 904-915
Guidelines for point‐of‐care testing: haematology
Summary: This guideline provides a framework for the arrangement of point‐of‐care testing (POCT) services, previously known as near patient testing (patient self‐testing not covered). POCT is defined as any analytical test performed outside the laboratory. Primary users are often non‐laboratory healthcare workers. The guidance applies to units within hospitals as well as general practioner surgeries, community clinics and pharmacies. The head of the haematology laboratory or a point of care coordinator must take responsibility for all aspects of the POCT service, including quality and training. Depending on the size and nature of the POCT practice, a local POCT manager may also be required. Equipment selected should have received a successful independent performance evaluation. If an independent evaluation has not been performed the purchaser should assess the device according to the protocol in this document. POCT devices should generate results that are comparable to those of the local laboratory. An accredited external quality assessment programme and internal quality control system must be established. Manufacturers promoting POCT devices designed for non‐laboratory sites, e.g. pharmacies, should undertake training and annual competency assessment, perhaps using a web‐based system. A diagram to illustrate the stages for the implementation of a POCT service is illustrated.
- 10 March 2008
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 30 (2) , 105-116
ICSH Guideline for worldwide point‐of‐care testing in haematology with special reference to the complete blood count
Summary: These guidelines provide information on how to develop and manage a point‐of‐care (POCT) service so that reliable haematology results are produced regardless of where the test is performed. Many of the issues addressed here are relevant to POCT within hospitals or health centres; however, the principles are equally applicable to care in the community and doctors’ offices. Other aspects discussed in this guideline are the initiation of the service (including indications for and limitations of a POCT service), staff training, type of haematology equipment selected, the blood results, monitoring of quality, accreditation, safety and cost. Equipment selected should generate results that are comparable to those of the local reference laboratory. If a complete independent evaluation of the POCT device has not been performed, the purchaser should perform a local assessment according to the protocol in this document. A literature search should also be undertaken to find independent peer reviewed evaluations on POCT equipment. Often the ideals discussed here may not be achievable in some developing countries but long‐term training and education of POCT workers needs to be supported and constantly kept on government agendas to reach the recommendations advised here. Users should interpret these recommendations for their particular POCT needs and setting.
- 10 March 2008
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 30 (2) , 105-116
ICSH Guideline for worldwide point‐of‐care testing in haematology with special reference to the complete blood count
Summary: These guidelines provide information on how to develop and manage a point‐of‐care (POCT) service so that reliable haematology results are produced regardless of where the test is performed. Many of the issues addressed here are relevant to POCT within hospitals or health centres; however, the principles are equally applicable to care in the community and doctors’ offices. Other aspects discussed in this guideline are the initiation of the service (including indications for and limitations of a POCT service), staff training, type of haematology equipment selected, the blood results, monitoring of quality, accreditation, safety and cost. Equipment selected should generate results that are comparable to those of the local reference laboratory. If a complete independent evaluation of the POCT device has not been performed, the purchaser should perform a local assessment according to the protocol in this document. A literature search should also be undertaken to find independent peer reviewed evaluations on POCT equipment. Often the ideals discussed here may not be achievable in some developing countries but long‐term training and education of POCT workers needs to be supported and constantly kept on government agendas to reach the recommendations advised here. Users should interpret these recommendations for their particular POCT needs and setting.
- Open Access
- 1 November 2006
- Published by Wiley in British Journal of Haematology
- Vol. 135 (3) , 416-417
Discrepancy between impedance and immunofluorescence platelet counting has implications for clinical decision making in patients with idiopathic thrombocytopenia purpura
- 1 November 2006
- Published by Wiley in British Journal of Haematology
- Vol. 135 (3) , 416-417
Open AccessDiscrepancy between impedance and immunofluorescence platelet counting has implications for clinical decision making in patients with idiopathic thrombocytopenia purpura
- 30 March 2006
- Published by Wiley in Transfusion Medicine
- Vol. 16 (2) , 101-109
Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation
summary. The decision to prophylactically transfuse platelets is dependent on the platelet count, careful regular clinical assessment and agreed local protocol. The ability to predict when platelet recovery will occur should allow a more reasoned approach to platelet transfusion. An increase in reticulated platelets demonstrates impending platelet recovery. A new rapid automated method to assess reticulated platelets, the immature platelet fraction (IPF), is described, and its clinical utility assessed.The IPF is identified by flow cytometry with the use of a nucleic acid specific dye in the reticulocyte channel on the Sysmex XE‐2100. Fifty healthy adult volunteers were used to establish the normal range. Patients where platelet marrow production or destruction might be abnormal were studied, and some patients followed serially during treatment. Thirty patients receiving cytotoxic chemotherapy were tested, and 13 of these patients followed serially. Fifteen patients post‐autologous or allogeneic transplant were followed daily for platelet count and IPF percentage to monitor platelet recovery.The method demonstrates good reproducibility and stability. The recovery phase of thrombocytopenia in most chemotherapy and transplant patients was preceded by a rise in IPF percentage several days prior to platelet recovery. In particular, patients undergoing autologous transplantation (n = 8) using peripherally collected stem cells have a characteristic IPF percentage motif, with a rise one or two days prior to engraftment.The automated IPF is a useful parameter in the clinical evaluation of the thrombocytopenic patient and has the potential to allow optimal transfusion of platelet concentrates.
- 30 March 2006
- Published by Wiley in Transfusion Medicine
- Vol. 16 (2) , 101-109
Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation
summary. The decision to prophylactically transfuse platelets is dependent on the platelet count, careful regular clinical assessment and agreed local protocol. The ability to predict when platelet recovery will occur should allow a more reasoned approach to platelet transfusion. An increase in reticulated platelets demonstrates impending platelet recovery. A new rapid automated method to assess reticulated platelets, the immature platelet fraction (IPF), is described, and its clinical utility assessed.The IPF is identified by flow cytometry with the use of a nucleic acid specific dye in the reticulocyte channel on the Sysmex XE‐2100. Fifty healthy adult volunteers were used to establish the normal range. Patients where platelet marrow production or destruction might be abnormal were studied, and some patients followed serially during treatment. Thirty patients receiving cytotoxic chemotherapy were tested, and 13 of these patients followed serially. Fifteen patients post‐autologous or allogeneic transplant were followed daily for platelet count and IPF percentage to monitor platelet recovery.The method demonstrates good reproducibility and stability. The recovery phase of thrombocytopenia in most chemotherapy and transplant patients was preceded by a rise in IPF percentage several days prior to platelet recovery. In particular, patients undergoing autologous transplantation (n = 8) using peripherally collected stem cells have a characteristic IPF percentage motif, with a rise one or two days prior to engraftment.The automated IPF is a useful parameter in the clinical evaluation of the thrombocytopenic patient and has the potential to allow optimal transfusion of platelet concentrates.
- 12 May 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (1) , 93-99
Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia
Summary: A new automated method to reliably quantify reticulated platelets, expressed as the immature platelet fraction (IPF), has been developed utilizing the XE‐2100 blood cell counter with upgraded software (Sysmex, Kobe, Japan). The IPF is identified by flow cytometry techniques and the use of a nucleic acid specific dye in the reticulocyte/optical platelet channel. The clinical utility of this parameter was established in the laboratory diagnosis of thrombocytopenia due to increased peripheral platelet destruction, particularly autoimmune thrombocytopenic purpura (AITP) and thrombotic thrombocytopenic purpura (TTP). Reproducibility and stability results over 48 h were good. An IPF reference range in healthy individuals was established as 1·1–6·1%, with a mean of 3·4%. Patients in whom platelet destruction might be abnormal, were studied and two of these patients followed serially during the course of treatment. The IPF was raised in several disease states. The most significant increases in IPF values were found in patients with AITP (mean 22·3%, range 9·2–33·1%) and acute TTP (mean 17·2%, range 11·2–30·9%). Following patients during treatment demonstrated that as the platelet count recovered the IPF% fell. These results show that a rapid, inexpensive automated method for measuring the IPF% is feasible and should become a standard parameter in evaluating the thrombocytopenic patient.
- 12 May 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (1) , 93-99
Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia
Summary: A new automated method to reliably quantify reticulated platelets, expressed as the immature platelet fraction (IPF), has been developed utilizing the XE‐2100 blood cell counter with upgraded software (Sysmex, Kobe, Japan). The IPF is identified by flow cytometry techniques and the use of a nucleic acid specific dye in the reticulocyte/optical platelet channel. The clinical utility of this parameter was established in the laboratory diagnosis of thrombocytopenia due to increased peripheral platelet destruction, particularly autoimmune thrombocytopenic purpura (AITP) and thrombotic thrombocytopenic purpura (TTP). Reproducibility and stability results over 48 h were good. An IPF reference range in healthy individuals was established as 1·1–6·1%, with a mean of 3·4%. Patients in whom platelet destruction might be abnormal, were studied and two of these patients followed serially during the course of treatment. The IPF was raised in several disease states. The most significant increases in IPF values were found in patients with AITP (mean 22·3%, range 9·2–33·1%) and acute TTP (mean 17·2%, range 11·2–30·9%). Following patients during treatment demonstrated that as the platelet count recovered the IPF% fell. These results show that a rapid, inexpensive automated method for measuring the IPF% is feasible and should become a standard parameter in evaluating the thrombocytopenic patient.